|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||126.17 - 128.30|
|52 Week Range||122.15 - 148.32|
|PE Ratio (TTM)||267.22|
|Earnings Date||Jul 17, 2018|
|Forward Dividend & Yield||3.36 (2.57%)|
|1y Target Est||149.05|
Kentucky Governor Matt Bevin discusses his state District Attorney suing Johnson & Johnson for contributing to the opioid epidemic through deceptive marketing.
Wall Street Journal columnist Veronica Dagher, Fox News political contributor Tammy Bruce and Fox News contributor Robert Wolf on the strength of the U.S. economy and how President Trump’s tax cuts have impacted consumers.
Earnings per share were higher despite a higher tax rate and a lower contribution from other income. What we didn’t like about the first quarter: 1) the pharma mix was not optimal, as key drugs Actelion, Darzalex, and Xarelto all missed our estimate. U.S. Remicade was down 16% Y/Y, in line with our estimate, but we were hoping for better.
After a spell of high volatility driven by uncertainty over global trade policy and the threat of rise in prices of essential commodities, Wall Street is looking for some respite in the upcoming earnings season. Given the positive trend, investing in blue-chip stocks that are likely to make the most of the earnings season seems judicious. This is because such stocks are positioned to report impressive earnings results as they mostly have a strong balance sheet and solid cash flow.
Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.
Pharmaceutical and biotech stocks are rarely seen as effective dividend stocks. Although drugs are also relatively non-cyclical these stocks are often impacted by ever-changing regulatory environment and the strength ofRead More...
issues were still top of mind to just about everyone as investors continued to drive the stock down as well. It's tough for some investors to find a positive view of the Seattle-based coffee house company. It's been trading sideways for close to three years, producing a 2% return over the last 12 months compared with 15% for the S&P and a somewhat pricey 21 times P/E multiple for a food and beverage company, all of which make an unappetizing menu choice for investors, never mind the company's moral and ethical dilemmas, says Stephen Guilfoyle.
The major equity indexes barely moved today, as a postearnings drop from International Business Machines (IBM) was canceled out by gains from Textron (TXT), Intuitive Surgical (ISRG), and others. Ultimately, it shows once again that it's as much a market of stocks as it is a stock market. The Dow Jones Industrial Average dropped 38.56 points, or 0.2%, to 24,748.07, while the S&P 500 ticked up 0.1% to 2708.64, and the Nasdaq Composite advanced 0.2% to 7295.24.
"I'm not on board with just about anything that he does," Gov. Matt Bevin said of Kentucky Attorney General Andy Beshear.
Kentucky's attorney general on Wednesday sued Johnson & Johnson, accusing the pharmaceutical manufacturer of devising a deceptive marketing scheme that mischaracterized the risk of opioid abuse and addiction. The lawsuit by Kentucky Attorney General Andy Beshear was his fifth to date seeking to hold a drug manufacturer or distributor responsible for its role in the national opioid epidemic.
The Dow Jones Industrial Average on Wednesday morning was wrestling with sharp declines in IBM and Johnson & Johnson. Shares of International Business Machines Corp. were off 7.2%, or about $11.50, which equates to a drop of about 80 points, while J&J's stock was contributing a further 24-point retreat in the benchmark, down 2.7%, or about $3.50, in recent action. Overall, the Dow was still managing to rise by about 24 points, or less than 0.1%, at 24,802, with J&J and IBM's tumble slightly offset by gains in Home Depot Inc. Caterpillar Inc. and Boeing Co. 's stocks.
This $18 million building will be next to the Sanford Burnham Prebys Medical Discovery Institute in southeast Orlando.
Resumes are a poor proxy for a human being. Whether on paper or LinkedIn, they may tell an employer about a job seeker’s experience and credentials, but they’re frustratingly silent about almost everything else. They have virtually nothing to say about a candidate’s personality, or their character, or their ability to persuade and communicate—all soft…
Johnson & Johnson reported higher-than-expected sales in its latest quarter and boosted its sales outlook for the year despite ongoing pricing pressures for its prescription drugs and medical devices. J&J said it planned to cut costs in its supply chain by $600 million to $800 million a year by 2022. To carry out the changes, J&J expects it will take $1.9 billion to $2.3 billion in charges over the next several years.
The U.S. government on Tuesday proposed tightening rules governing the amount of prescription opioid painkillers that drugmakers can manufacture in a given year, in hopes of reining in the deadly opioid epidemic. The Drug Enforcement Administration's proposed changes to its regulations over addictive drug manufacturing quotas were announced by Attorney General Jeff Sessions. The plan could sharply reduce the annual production of painkillers.
Trade, taxes and China are the main themes to watch for heading into first-quarter earnings, along with a spate of potential deals.
Stocks that moved substantially or traded heavily Tuesday: UnitedHealth Group Inc., up $8.23 to $238.55 The health insurer raised its annual profit forecast after a strong first quarter. Tesla Inc., down ...